Iovance Reports Promising 26% Response Rate for Lifileucel TIL Therapy in Advanced NSCLC
核心洞察
Iovance Biotherapeutics announced interim data from its Phase 2 IOV-LUN-202 trial showing lifileucel achieved a 25.6% objective response rate in previously treated advanced nonsquamous NSCLC patients.
The median duration of response was not reached after 25.4 months of follow-up, demonstrating unprecedented durability compared to standard-of-care docetaxel which shows 12.8% response rate and 5.6 months duration.
The FDA has provided positive regulatory feedback on the trial design, with lifileucel expected to launch in the second half of 2027 following supplemental BLA submission.
Iovance Biotherapeutics reported interim data from its registrational Phase 2 IOV-LUN-202 trial demonstrating that lifileucel, a tumor infiltrating lymphocyte (TIL) therapy, achieved a 25.6% objective response rate in patients with previously treated advanced nonsquamous non-small cell lung cancer (NSCLC). The results represent a significant advancement for patients with limited treatment options following initial immune checkpoint inhibitor therapy.
Clinical Efficacy Results
The interim analysis included 39 patients with advanced nonsquamous NSCLC without actionable genetic mutations who had previously received immune checkpoint inhibitor and chemotherapy treatment. Lifileucel monotherapy demonstrated an objective response in 10 patients, including 2 complete responses, 7 partial responses, and 1 unconfirmed partial response pending confirmatory assessment. The disease control rate reached 71.8%.
Notably, the median duration of response was not reached after a median follow-up of 25.4 months, indicating unprecedented durability for this patient population. This compares favorably to standard-of-care docetaxel monotherapy, which recently showed an objective response rate of 12.8% with a median duration of response of 5.6 months and overall survival of 12.3 months, without any complete responses.
"It is exciting to see such an impressive response rate and durability observed in previously treated patients with NSCLC, because today there are only very limited treatment options, none of which demonstrate this quality of response and durability," said Martin Wermke, M.D., Professor for Experimental Cancer Therapy and Director at the National Center for Tumor Diseases Dresden (搜索).
Safety Profile and Treatment Optimization
The safety profile for lifileucel was consistent with the underlying disease, non-myeloablative lymphodepletion, and interleukin-2 administration. Importantly, Iovance implemented an updated regimen with reduced non-myeloablative lymphodepletion that improved the overall safety profile without affecting efficacy.
Patients treated with the updated regimen showed a reduction of median post-IL-2 hospitalization days by more than half and experienced lower incidence and shorter time to resolution of cytopenias compared with the initial regimen.
Regulatory Pathway and Commercial Timeline
The U.S. Food and Drug Administration previously provided positive regulatory feedback on the IOV-LUN-202 trial design and the proposed potency assay matrix to support registration. The trial design aligns with FDA guidance for single-arm trials to support accelerated approvals in conditions with unmet medical need.
The IOV-LUN-202 trial is expected to progress in 2026 towards a supplemental Biologics License Application for lifileucel in nonsquamous NSCLC, with a potential commercial launch anticipated in the second half of 2027. Enrollment for the study is expected to be completed during the second half of 2026.
Market Context and Unmet Need
Lung cancer represents the most commonly diagnosed cancer and leading cause of cancer death worldwide, with an estimated 2.5 million new cases and 1.8 million deaths globally each year. In the United States, approximately 226,000 new cases and 125,000 deaths occur annually. Approximately 85% of lung cancer cases are NSCLC, with non-squamous NSCLC representing an estimated 75% of NSCLC cases.
Following initial treatment with immune checkpoint inhibitors and chemotherapy, patients with advanced NSCLC face limited treatment options and often receive chemotherapy with limited durability.
TIL Therapy Mechanism
Tumor infiltrating lymphocytes are naturally occurring immune cells that recognize, attack, and kill cancer cells through tumor markers unique to each patient. The majority of solid tumor immune targets are patient-specific, with fewer than 1% shared among patients.
TIL cell therapy involves collecting a patient's naturally occurring TIL cells from their tumor tissue and expanding them outside the body using Iovance's proprietary manufacturing process. The individualized therapy represents a one-time treatment that deploys billions of personalized, patient-specific TIL cells to recognize, target, and destroy diverse cancer cells.
"Lifileucel has demonstrated a potentially best-in-class clinical profile in previously treated advanced nonsquamous NSCLC. The duration of response is unprecedented and is combined with an impressive response rate in a one-time monotherapy for a difficult-to-treat patient population," stated Friedrich Graf Finckenstein, M.D., Chief Medical Officer of Iovance. "We will pursue regulatory approvals for lifileucel monotherapy to effectively address the tens of thousands of patients with previously treated nonsquamous advanced NSCLC."
Iovance plans to present additional data from the IOV-LUN-202 trial at an upcoming medical meeting in 2026.